ClinVar Miner

Submissions for variant NM_000546.6(TP53):c.97-4_104del

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV003171491 SCV003856750 pathogenic Hereditary cancer-predisposing syndrome 2022-11-01 criteria provided, single submitter clinical testing The c.97-4_104del12 pathogenic mutation results from a deletion of 12 nucleotides between positions c.97-4 and c.104 and involves the canonical splice acceptor site before coding exon 3 of the TP53 gene. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site. The stop codon in the predicted resulting transcript occurs in the 5' end ofthe TP53 gene. As such, this alteration may escape nonsense-mediated mRNAdecay and/or be prone to rescue by re-initiation (Rivas et al. Science. 2015 May 8;348(6235):666-9; Lindeboom et al. Nat Genet. 2016 Oct;48(10):1112-8; Rhee et al. Sci Rep. 2017 May 10;7(1):1653). The exact functional effect of this alteration is unknown; however, the impacted region is critical for protein function (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). As such, this alteration is interpreted as a disease-causing mutation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.